Success Stories: A Director Achieves NIW Approval for Groundbreaking Cancer Research Without an RFE

Posted by wegreened on January 30, 2026 in General Medicine (Public Health, Clinical Research, Infectious Diseases, Vaccines, Virology, Epidemiology, Clinical Psychology, Psychiatry), NIW

Client’s Testimonial:

“Thank you. This is the most uplifting news I’ve received for quite a few months now.”

On October 22^nd, 2025, we received another I-140 NIW (National Interest Waiver) approval for a Director in the field of Clinical Medicine (Approval Notice).

General Field: Clinical Medicine

Position at the Time of Case Filing: Director

Country of Origin: Taiwan

Country of Residence at the Time of Filing: Taiwan

Approval Notice Date: October 22^nd, 2025

Processing Time: 4 months, 24 days

Case Summary:

We are delighted to share the success story of an EB-2 NIW (National Interest Waiver) approval for a Director of the Surgery Department in the field of clinical medicine. The client holds a Ph.D. in mechanical engineering and a medical degree. With our assistance, the petition was successfully approved in just over four months without receiving a Request for Evidence (RFE).

Research with Substantial Merit and National Importance:

In the NIW petition, NAILG highlighted that the client’s proposed endeavor focuses on using big data analytics to identify key factors contributing to urological cancers and chronic diseases, with the ultimate goal of developing mitigation and prevention strategies. Through advanced data modeling that integrates electronic health records, genomic data, and biochemical profiles, the client’s research enhances understanding of cancer mechanisms and informs more effective treatments.

This endeavor aligns closely with U.S. national priorities in precision medicine, cancer prevention, and digital health innovation, advancing the mission of agencies such as the National Cancer Institute and the Centers for Disease Control and Prevention (CDC) to apply data science in improving population health.

To further strengthen the petition, we highlighted the client’s exceptional qualifications:

Publications: The client has authored 7 peer-reviewed journal articles (3 first-authored) and 7 abstracts (4 first-authored), including publications in highly ranked journals.
Citations: The client’s work has accumulated 55 citations, demonstrating significant influence within the scientific community. This outstanding citation performance objectively demonstrates the major impact and originality of the client’s contributions.

NIW Approval and Outlook:

This successful outcome underscores NAILG’s dedication to supporting medical innovators whose work is transforming the future of healthcare and cancer prevention. With over 32,000 cases successfully handled, NAILG has a proven track record of excellence in guiding professionals through the immigration process. In this case, the client’s leadership in merging clinical medicine with big data analytics holds the potential to drive significant advancements in urological oncology, early disease detection, and evidence-based treatment. These efforts will not only accelerate medical breakthroughs but also enhance the quality of life for patients across the United States and beyond.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2020.01 - 2024.12)

Category	Approval or Refund^®		Approval or Refiling^TM
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	28,946	99.52%	3,030	98.31%
EB1A	4,322	91.76%	2,870	88.91%
EB1B	793	98.51%	236	90.77%
Total	34,061	98.44%	6,136	93.39%